REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1606146
This article is part of the Research TopicPharmacology of Natural Products against Neurodegenerative DisordersView all 16 articles
Preclinical and Experimental Evidence of Salvianolic Acid B in the Treatment of Neurological Diseases
Provisionally accepted
- 1Department of Neurosurgery, Northern Theater General Hospital, Shenyang, China
- 2Department of Neurosurgery, The Eleventh People's Hospital of Shenyang, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Neurological diseases such as stroke and Alzheimer's disease pose increasing challenges to global public health. Salvianolic Acid B (SalB), a major active component of Salvia miltiorrhiza, has garnered attention due to its anti-inflammatory, antioxidant, neuroprotective, and pro-angiogenic properties in neurological disease treatment.Purpose: This paper aims to review the mechanisms and effects of SalB in the treatment of neurological diseases, exploring its role in improving neurological function, mitigating neuroinflammation, and reducing oxidative stress.Results: SalB demonstrates multifaceted mechanisms in neurological disease management. In animal models of cerebral ischemia/reperfusion injury, SalB reduces infarct size and enhances neurological recovery via anti-inflammatory, anti-oxidative stress, and angiogenic pathways. It protects the blood-brain barrier and inhibits neuronal apoptosis in stroke models. In spinal cord injury models, SalB alleviates edema and promotes motor function recovery. In Alzheimer's disease models, SalB suppresses amyloid-beta formation and neuroinflammation. Additionally, SalB exhibits antidepressant and analgesic effects in pain-depression comorbidity models. These effects are mediated through the regulation of signaling pathways, including NF-κB, AMPK, PI3K/Akt, and Nrf2, highlighting SalB's broad therapeutic potential in neurological diseases.Conclusion: SalB exhibits promising prospects in the treatment of neurological diseases. However, its clinical application faces challenges such as chemical stability and bioavailability.Further research on the mechanisms of SalB and innovative drug delivery strategies is needed to advance its application in neurological disease therapy.
Keywords: salvianolic acid B, Neurological Diseases, anti-inflammatory, anti-oxidative stress, neuroprotective, Angiogenesis, Signaling Pathways
Received: 14 Apr 2025; Accepted: 20 Jun 2025.
Copyright: © 2025 Bi, Liu, Zhu, Gao, Chen, Yu and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ligang Chen, Department of Neurosurgery, Northern Theater General Hospital, Shenyang, China
Chunyong Yu, Department of Neurosurgery, Northern Theater General Hospital, Shenyang, China
Guobiao Liang, Department of Neurosurgery, Northern Theater General Hospital, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.